ARTICLE | Top Story
Metabolex, sanofi in diabetes deal
June 25, 2010 11:15 PM UTC
Metabolex Inc. (Hayward, Calif.) granted sanofi-aventis Group (Euronext:SAN; NYSE:SNY) exclusive, worldwide rights to develop and commercialize MBX-2982 and undisclosed preclinical compounds. MBX-2982 is a G protein-coupled receptor 119 (GPR119) agonist that is in Phase II testing for Type II diabetes. Metabolex could receive up to $375 million from the deal, including upfront and milestone payments. Metabolex also is eligible for royalties. ...